http://www.ova-1.com

Helping Guide Surgical Decisions

Announcing OVA1™

The Landmark Ovarian Cancer Diagnostic Test

OVA1™ is the first and only blood test cleared to help a physician evaluate the likelihood that a woman's ovarian mass is malignant or benign in conjunction with the physician's evaluation prior to a planned surgery

OVA1™ is indicated for use in women who are over 18 years of age; have an ovarian mass present for which surgery is planned; and have not yet been referred to an oncologist

OVA1™ provides new, objective information for physicians referring women to the most appropriate surgeon to operate on their ovarian mass -- potentially helping promote better treatment outcomes.

Developed by Vermillion, Inc., OVA1™ is now available nationally to women and their physicians through Quest Diagnostics.

OVA1™ is a qualitative serum test that combines the results of five immunoassays into a single numerical result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. OVA1™ is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test is not intended as a screening or stand-alone diagnostic assay.

PRECAUTION: The OVA1™ Test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of OVA1™ carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Vermillion and OVA1 are trademarks of Vermillion, Inc.